
|Videos|March 30, 2018
Managing Relapsed Follicular Lymphoma
Managing Relapsed Follicular Lymphoma
Advertisement
June 2015
- A 65-year old female presented to her PCP complaining of night sweats and swelling in the neck
- PMH: osteoporosis, neurogenic bladder
- Physical examination:
- Enlarged spleen 2 cm. below costal margin, bilateral cervical and axillary lymphadenopathy
- ECOG 0
- Laboratory findings:
- WBC: 12 x 109/L; 45% lymphocytes
- Hb: 11.5 g/dL
- Platelets: 213 x 109/L
- LDH 212 U/L
- Excisional biopsy of the lymph nodes:
- IHC: CD10+, BCL2+
- Follicular lymphoma, grade IIIa
- Bone marrow biopsy, 40% involved
- 18FDG-PET showed SUVmax of 9 with discrete masses bilaterally in the cervical and axillary region and increased uptake in the liver
- FLIPI 4 points, high risk
- The patient was started on bendamustine + rituximab (6 cycles) and was continued on rituximab maintenance therapy for 12 months
- She achieved a partial response with a 75% reduction in tumor volume
February 2018
- After 32 months, the patient complained of her symptoms returning
- CT showed disease progression in the axillary and hilar lymph nodes
- PET with SUV of 11
- Re-biopsy of lymph node, consistent with follicular lymphoma grade IIIa
- The patient was referred to an academic center for treatment
- She was enrolled in an open-label clinical trial of lenalidomide/rituximab (12 cycles)
- She achieved partial remission after 3 months
February 2019
- Twelve months later, the patient presents with low-grade fever and chills, she is otherwise well-appearing and continues to exercise regularly
- ECOG 0
- PET-CT showed further progression in the axillary lymph nodes
- The patient was treated with IV copanlisib and achieved a partial response after 4 cycles; she continues to do well on therapy
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
3
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5








































